What is Cagent Vascular?
Cagent Vascular Inc. is a medical technology innovator focused on the development of advanced angioplasty balloons. At the core of its product portfolio is the proprietary Serration Technology, which is engineered to enhance the efficacy of vascular interventions. The company's flagship product, the Serranator, is specifically designed to optimize lumen gain while simultaneously mitigating the risks of complications during complex cardiovascular procedures. By addressing critical gaps in current treatment standards, Cagent Vascular provides healthcare professionals with precision tools aimed at improving patient outcomes and long-term quality of life for those suffering from cardiovascular disease.
How much funding has Cagent Vascular raised?
Cagent Vascular has raised a total of $107M across 6 funding rounds:
Series B
$11.9M
Debt
$150K
Private Equity
$9M
Series C
$30M
Private Equity
$15M
Private Equity
$24.5M
Series B (2018): $11.9M with participation from Ben Franklin Technology Partners, Balestier Investments, and Synergy Ventures
Debt (2020): $150K led by PPP
Private Equity (2021): $9M supported by Sectoral Asset Management
Series C (2024): $30M featuring Blue Ridge Medical Center and Sectoral Asset Management
Private Equity (2025): $15M backed by Trinity Capital
Private Equity (2026): $24.5M, investors not publicly disclosed
Key Investors in Cagent Vascular
Sectoral Asset Management
An investment advisor specializing in managing equities globally within the healthcare sector, with a strong focus on biotech and medical device strategies.
Blue Ridge Medical Center
A specialized medical provider offering comprehensive services in cardiology and internal medicine, committed to advancing patient care through clinical excellence.
Ben Franklin Technology Partners
A regional investment partner focused on fostering technological innovation and supporting the growth of early-stage companies through strategic capital and resources.
What's next for Cagent Vascular?
With the recent capital injection, Cagent Vascular is well-positioned to scale its operational capabilities and expand the clinical adoption of its Serration Technology. The strategic focus will likely shift toward deepening market penetration within the cardiovascular intervention sector and potentially diversifying its product pipeline to address additional vascular pathologies. By leveraging this latest round of financing, the company aims to solidify its status as a leader in medical device innovation, ensuring that its proprietary technology becomes a standard component of modern angioplasty protocols. Future growth will be defined by the company's ability to translate its clinical advantages into sustained commercial success across diverse healthcare markets.
See full Cagent Vascular company page
